FindTrial
Sign In

PegIntron

DRUG8 trials

Sponsors

University Hospital, Bordeaux, Merck Sharp & Dohme LLC, Thomas Stauffer Larsen, Biocad

Conditions

Chronic Hepatitis CEssential ThrombocythemiaHepatitisHepatitis CHepatitis C/ Human Immunodeficiency Virus CoinfectionMelanomaNeoplasm MetastasisPolycythemia Vera

Phase 2

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
CompletedNCT01740089
BiocadHepatitis, Hepatitis C
Start: 2011-11-30End: 2013-12-31Updated: 2015-08-18

Phase 3

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
CompletedNCT00221702
University Hospital, BordeauxMelanoma, Neoplasm Metastasis
Start: 2003-06-30End: 2010-10-31Updated: 2010-10-13
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
CompletedNCT01387763
Thomas Stauffer LarsenEssential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Start: 2012-01-31End: 2020-06-30Updated: 2022-04-27
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
CompletedNCT02103439
BiocadHepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
Start: 2013-06-06End: 2015-08-26Updated: 2018-08-09
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
WithdrawnNCT02204475
Merck Sharp & Dohme LLCHepatitis C
Start: 2014-11-30End: 2016-09-30Updated: 2015-10-14
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
CompletedNCT02358044
Merck Sharp & Dohme LLCHepatitis C
Start: 2015-02-27End: 2016-02-16Updated: 2018-10-03

Unknown Phase

Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
CompletedNCT00704964
Merck Sharp & Dohme LLCChronic Hepatitis C, Hepatitis C
Start: 2005-05-31End: 2009-10-31Updated: 2015-10-06
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
CompletedNCT00709228
Merck Sharp & Dohme LLCHepatitis C
Start: 2006-05-31End: 2008-11-30Updated: 2015-01-26

Related Papers

Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark
EClinicalMedicine2026-09-09
Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms
Cancers2026-08-06
Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms - Baseline Data from the Daliah Trial
Blood2024-11-05
Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN
Blood2023-11-029 citations
Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms
Blood2022-11-15
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
Blood Advances2021-09-1058 citations
Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response
Blood2019-11-131 citations
S1609 THREE‐YEAR ANALYSIS OF THE DALIAH TRIAL ‐ A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA‐2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
HemaSphere2019-06-014 citations
PB2210 IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA‐2 OR HYDROXYUREA IN THE DALIAH TRIAL
HemaSphere2019-06-01
Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
Patient Preference and Adherence2018-12-018 citations
Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial
Blood2018-11-2917 citations
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
2018-01-1736 citations
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection
Hepatology Communications2017-08-229 citations
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
2016-08-1638 citations
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
2012-09-1026 citations